SOUTH SAN FRANCISCO, Calif, April 25, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the ...
Presentation of encouraging preclinical results for CER-1236 in ovarian cancer, indicating potential effectiveness of the treatment. No observed toxicity in animal models after treatment, highlighting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback